A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.

Abstract

AIMS:

The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients with the metabolic syndrome.

METHODS AND RESULTS:

Patients with the metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) > or =3.36 mmol/L (130 mg/dL) and multiple risk factors conferring a 10-year coronary heart disease risk score of >10% were randomized (2:2:1) to receive rosuvastatin 10 mg, atorvastatin 10 mg, or placebo for 6 weeks. Subsequently, the rosuvastatin 10 mg and placebo groups received rosuvastatin 20 mg and the atorvastatin 10 mg group received atorvastatin 20 mg for 6 weeks. LDL-C was reduced significantly more in patients receiving rosuvastatin 10 mg when compared with those receiving atorvastatin 10 mg at 6 weeks [intention-to-treat (ITT) population by randomized treatment: 41.7 vs. 35.7%, P < 0.001; ITT population by as-allocated treatment: 42.7 vs. 36.6%, P < 0.001]. Significant LDL-C reductions were also observed in patients receiving rosuvastatin when compared with those receiving atorvastatin at 12 weeks (48.9 vs. 42.5%, P < 0.001). More patients achieved LDL-C goals with rosuvastatin when compared with atorvastatin. Rosuvastatin increased high-density lipoprotein cholesterol significantly more than atorvastatin. Treatments were well tolerated.

CONCLUSION:

At equivalent doses, rosuvastatin had a significantly greater effect than atorvastatin in lowering LDL-C and improving the lipid profile and was well tolerated in patients with the metabolic syndrome.

• Authors: Anton F H Stalenhoef, Christie M Ballantyne, Cinzia Sarti, Jan Murin, Serena Tonstad, Helen Rose, Wim Wilpshaar
• Journal: European heart journal (Eur Heart J) Vol. 26 Issue 24 Pg. 2664-72 (Dec 2005) ISSN: 0195-668X [Print] England
• PMID: 16143705 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Fluorobenzenes
• Heptanoic Acids
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids
• Pyrimidines
• Pyrroles
• Sulfonamides
• Rosuvastatin Calcium
• C-Reactive Protein
• Atorvastatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Analysis of Variance
• Atorvastatin
• C-Reactive Protein (metabolism)
• Double-Blind Method
• Female
• Fluorobenzenes (therapeutic use)
• Heptanoic Acids (therapeutic use)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Lipids (blood)
• Male
• Metabolic Syndrome (blood, drug therapy)
• Middle Aged
• Prospective Studies
• Pyrimidines (therapeutic use)
• Pyrroles (therapeutic use)
• Rosuvastatin Calcium
• Sulfonamides (therapeutic use)
• Treatment Outcome